STOCKHOLM, Sweden & PITTSBURGH--(BUSINESS WIRE)--Regulatory News:
Diamyd Medical AB (www.omxgroup.com) (NASDAQ:DMYDY) (STO:DIAMB):
Diamyd Medical announces that it is submitting an IND today for NP2, the company’s first drug candidate in its Nerve Targeting Drug Delivery System (NTDDS) gene therapy platform, to the US Food and Drug Administration (FDA). Pending a favorable review by the agency, Diamyd plans to initiate a Phase I clinical study. NP2, developed by the company’s U.S. subsidiary, Diamyd, Inc., produces enkephalin locally in the targeted sensory neurons to block pain signals before they are transmitted through the spinal cord to the brain. This may reduce or eliminate the need for systemic pain treatment and avoid associated side effects.
